GlucoTrack Inc GCTK

RUTHERFORD, N.J. & LA JOLLA, Calif., October 01, 2026--Lōkahi expands its UGA collaboration internationally with Universität Paderborn, increasing ai² platform capacity and strategic revenue opportunities.

RUTHERFORD, N.J. & LA JOLLA, Calif., September 30, 2026--Lōkahi Therapeutics™ announces Qare™, a new comparative health platform for GLP-1 users, available beginning October 14, 2026.

RUTHERFORD, N.J. & LA JOLLA, Calif., September 25, 2026--Lōkahi Therapeutics™ partners with Pepperdine E2B™ to expand ai² Pipeline™, engaging MBA students in evaluating biopharmaceutical assets.

RUTHERFORD, N.J. & LA JOLLA, Calif., September 24, 2026--Glucotrack, Inc. Announces Pricing of $3 Million Public Offering.

RUTHERFORD, N.J. & LA JOLLA, Calif. & LOS ANGELES, September 23, 2026--Lōkahi Therapeutics™ Advances its Proprietary ai² PIPELINE Process from Internal Asset Engine to Revenue-Generating Platform.

RUTHERFORD, N.J. & LA JOLLA, Calif., September 23, 2026--Lōkahi CEO Erik Emerson outlines LT-100 progress, ai² platform growth, and a strategy to discover, advance, and monetize assets.

RUTHERFORD, N.J. & LA JOLLA, Calif., September 18, 2026--Lōkahi Therapeutics™ renews its University of Alabama collaboration, advancing real-world asset evaluation and developing key future biopharma talent.

RUTHERFORD, N.J. & LA JOLLA, Calif., September 11, 2026--Glucotrack announces $11.5M convertible note financing, including new capital and note rollover, to support strategic growth.

RUTHERFORD, N.J., & LA JOLLA, Calif., September 08, 2026--Lōkahi Therapeutics™ launches three ai² divisions to potentially drive revenue, expand partnerships, develop talent, and accelerate innovation.

RUTHERFORD, N.J., & LA JOLLA, Calif., September 02, 2026--Lōkahi Therapeutics™ expands its ai² Futures Lab™ network through a collaboration with SDSU Fowler College of Business to identify therapeutic assets.

RUTHERFORD, N.J. & LA JOLLA, Calif., August 27, 2026--Glucotrack (Nasdaq: GCTK) announced a 1-for-15 reverse stock split effective August 31, 2026, to support Nasdaq listing compliance.

RUTHERFORD, N.J. & LA JOLLA, Calif., August 25, 2026--Lōkahi Therapeutics™ initiates GMP manufacturing of LT-100 and advances preparations for the program's next clinical milestone.

RUTHERFORD, N.J. & LA JOLLA, Calif., August 21, 2026--Lōkahi and UGA launch an ai² Futures Lab initiative focused on sourcing and evaluating underdeveloped therapeutic assets for future growth.

Glucotrack (NASDAQ:GCTK) has regained compliance with Nasdaq’s stockholders’ equity requirement, with the Nasdaq Hearings Panel granting the company’s request for continued listing subject to certain conditions. The Nasdaq compliance milestone removes one specific listing issue for Glucotrack as management continues its strategic transformation, although the company said it is still working toward full compliance with all applicable Nasdaq standards.

RUTHERFORD, N.J. & LA JOLLA, Calif., August 17, 2026--"We are approaching the months ahead with confidence, urgency, and a clear sense of purpose," said Erik Emerson, CEO of Glucotrack.

NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. (“E.F. Hutton”), a leading investment banking and financial advisory firm, today announced that it acted as exclusive financial advisor in connection with a $5.5 million financing for Lōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. (Nasdaq: GCTK). The financing was led by participating institutional investors and consisted of a $2.0 million equity financing, priced at $0.75 per unit, together with a $3.5 million follow-on inves